References
2019 American Geriatrics Society Beers Criteria® Update Expert Panel. (2019). American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society, 67(4), 674-694. https://doi.org/10.1111/jgs.15767
Jordan, T. & Aiken, C. (2019). Mirtazapine augmentation: Running low on rocket fuel. The Carlat Report: Psychiatry, 17(9), 1-2.
Aiken, C. (2019). Is Paxil the best SSRI for anxiety? The Carlat Report: Psychiatry, 17(9), 4.
American Psychological Association. (2011). Practice guidelines regarding psychologists’ involvement in pharmacological issues. American Psychologist, 66(9), 835-849.
Funk, M. C., Beach, S. R., Bostwick, J. R., Celano, C. M., Hasnain, M., Pandurangi, A., Khandai, A. C., Taylor, A., Levenson, J. L., Riba, M., and Kovacs, R. J. (2018). Resource document on QTc prolongation and psychotropic medications. American Psychiatric Association. https://www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/
Centers for Disease Control and Prevention. (n.d.). Adverse Drug Events in Adults. https://www.cdc.gov/medicationsafety/adult_adversedrugevents.html
Choudhary, S., McLeod, M., Torchia, D., & Romanelli, P. (2013). Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. The Journal of Clinical and Aesthetic Dermatology, 6(6), 31–37.
FDA. (n.d.). FDA Adverse Event Reporting System (FAERS). https://www.fda.gov/drugs/drug-approvals-and-databases/fda-adverse-event-reporting-system-faers
Frey, N., Jossi, J., Bodmer, M., Bircher, A., Jick, S. S., Meier, C. R., & Spoendlin, J. (2017). The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. Journal of Investigative Dermatology 137(6), 1240-1247.
National Library of Medicine. (n.d.) Stevens-Johnson syndrome/toxic epidermal necrolysis. https://ghr.nlm.nih.gov/condition/stevens-johnson-syndrome-toxic-epidermal-necrolysis